Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.06
0.010.95%
At close: Jun 16, 5:00 PM EST
$1.05
-0.01-0.94%
After Hours: 9:28 AM EST
Cardiol Therapeutics Inc Analyst Ratings
CRDLNASDAQ
Cardiol Therapeutics Analyst Ratings and Price Targets | NASDAQ:CRDL | Benzinga
Cardiol Therapeutics Inc has a consensus price target of $7.8 based on the ratings of 5 analysts. The high is $10 issued by Roth MKM on June 26, 2024. The low is $3 issued by Cantor Fitzgerald on August 14, 2023. The 3 most-recent analyst ratings were released by Canaccord Genuity, HC Wainwright & Co., and HC Wainwright & Co. on April 6, 2026, February 10, 2026, and December 1, 2025, respectively. With an average price target of $8.67 between Canaccord Genuity, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 725.40% upside for Cardiol Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
HC Wainwright & Co.
HC Wainwright & Co.
Roth MKM
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for Cardiol Therapeutics
Loading calendar...
FAQ
What is the target price for Cardiol Therapeutics (CRDL) stock?
The latest price target for Cardiol Therapeutics (NASDAQ:CRDL) was reported by Canaccord Genuity on April 6, 2026. The analyst firm set a price target for $8.00 expecting CRDL to rise to within 12 months (a possible 661.90% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cardiol Therapeutics (CRDL)?
The latest analyst rating for Cardiol Therapeutics (NASDAQ:CRDL) was provided by Canaccord Genuity, and Cardiol Therapeutics maintained their buy rating.
When was the last upgrade for Cardiol Therapeutics (CRDL)?
There is no last upgrade for Cardiol Therapeutics
When was the last downgrade for Cardiol Therapeutics (CRDL)?
There is no last downgrade for Cardiol Therapeutics.
When is the next analyst rating going to be posted or updated for Cardiol Therapeutics (CRDL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cardiol Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cardiol Therapeutics was filed on April 6, 2026 so you should expect the next rating to be made available sometime around April 6, 2027.
Is the Analyst Rating Cardiol Therapeutics (CRDL) correct?
While ratings are subjective and will change, the latest Cardiol Therapeutics (CRDL) rating was a maintained with a price target of $8.00 to $8.00. The current price Cardiol Therapeutics (CRDL) is trading at is $1.05, which is out of the analyst’s predicted range.
